Compass Therapeutics, Inc.
CMPX
$5.22
-$0.10-1.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 0.00 | 850.00K | 850.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 0.00 | 850.00K | 850.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 0.00 | 0.00 | 850.00K | 850.00K |
| SG&A Expenses | 16.87M | 16.09M | 16.73M | 16.80M | 15.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.84M | 71.42M | 67.85M | 62.67M | 57.48M |
| Operating Income | -72.84M | -71.42M | -67.85M | -61.82M | -56.63M |
| Income Before Tax | -66.49M | -65.81M | -62.03M | -55.22M | -49.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -66.49 | -65.81 | -62.03 | -55.22 | -49.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.49M | -65.81M | -62.03M | -55.22M | -49.38M |
| EBIT | -72.84M | -71.42M | -67.85M | -61.82M | -56.63M |
| EBITDA | -72.56M | -71.02M | -67.32M | -61.25M | -56.04M |
| EPS Basic | -0.43 | -0.46 | -0.45 | -0.40 | -0.36 |
| Normalized Basic EPS | -0.27 | -0.29 | -0.28 | -0.25 | -0.23 |
| EPS Diluted | -0.43 | -0.46 | -0.45 | -0.40 | -0.36 |
| Normalized Diluted EPS | -0.27 | -0.29 | -0.28 | -0.25 | -0.23 |
| Average Basic Shares Outstanding | 630.14M | 581.93M | 550.73M | 550.04M | 548.41M |
| Average Diluted Shares Outstanding | 630.14M | 581.93M | 550.73M | 550.04M | 548.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |